(Q38424914)

3 September 2017

1 reference

title

Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer: bridging the gap between evidence and practice (English)

1 reference

3 September 2017

1 reference

John P Sfakianos

1

1 reference

PubMed ID

25882560

3 September 2017

Matthew D Galsky

series ordinal

2

1 reference

PubMed ID

25882560

3 September 2017

language of work or name

1 reference

5 March 2015

1 reference

Urologic Clinics of North America

3 September 2017

1 reference

3 September 2017

42

1 reference

3 September 2017

181-7, viii

1 reference

3 September 2017

2

1 reference

3 September 2017

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

Use of radical cystectomy for patients with invasive bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

Patterns of referral for perioperative chemotherapy among patients with muscle-invasive bladder cancer: a population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

Prediction of drug combination chemosensitivity in human bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

Comprehensive molecular characterization of urothelial bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

Cancer immunotherapy highlights from the 2014 ASCO Meeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.002

10.1016/J.UCL.2015.01.002

7 January 2021

Identifiers

DOI

1 reference

3 September 2017

1 reference

PubMed ID

25882560